APLT - NASDAQ
Applied Therapeutics, Inc.
$0.91
+0.0000%Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
At a Glance
Live Snapshotaplt
Selling, General and Administrative Expenses
Last Annual Value
56.01M
3-Year CAGR
9%
5-Year CAGR
33%
10-Year CAGR
58%
Applied Therapeutics, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Applied Therapeutics, Inc. NASDAQ:APLT | 56.01M | 39.5% | 5.4% | N/A | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 14.22M | 2.9% | 3.7% | -4.7% | |
 Alto Neuroscience, Inc. NYSE:ANRO | 20.75M | 40.3% | 40.8% | N/A | |
 Elicio Therapeutics, Inc. NASDAQ:ELTX | 12.81M | 2.5% | -6.3% | N/A | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 12.20M | 55.2% | N/A | N/A | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 39.16M | -20.4% | -10.8% | 1.8% | |
 Forte Biosciences, Inc. NASDAQ:FBRX | 12.41M | 5.3% | 10.2% | 11.3% | |
 Nkarta, Inc. NASDAQ:NKTX | 31.57M | -3.3% | 6.5% | N/A | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 15.21M | 3.0% | -5.7% | 8.9% | |
 PepGen Inc. NASDAQ:PEPG | 22.57M | 10.7% | 22.7% | N/A | |
 Rani Therapeutics Holdings, Inc. NASDAQ:RANI | 19.74M | -9.3% | -6.6% | N/A |
Applied Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your APLT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.